Outcome variables | Treatment (n = 42) Mean ± SD | Control (n = 42) Mean ± SD | Comparison of the groups | ||
---|---|---|---|---|---|
Adjusted MD (95%CI) | P | Partial Eta2 | |||
Total score (0–63) | |||||
Baseline | 33.8 ± 6.4 | 31.1 ± 6.3 | 2.7 (-0.1 to 5.4) | 0.059 | |
4 weeks | 16.7 ± 7.7 | 22.9 ± 9.2 | -7.8 (-11.1 to -4.4) | < 0.001 | 0.21 |
8 weeks | 8.0 ± 5.5 | 19.5 ± 11.0 | -12.9 (-16.2 to -9.3) | < 0.001 | 0.39 |
Vasomotor symptoms (0–6) | |||||
Baseline | 4.0 ± 1.7 | 3.5 ± 1.6 | 0.5 (-2.9 to 1.2) | 0.22 | |
4 weeks | 1.8 ± 2.0 | 2.6 ± 1.7 | -1.1 (-0.4 to -1.8) | 0.002 | 0.11 |
8 weeks | 0.7 ± 1.6 | 2.4 ± 1.8 | -1.9 (-1.2 to -2.6) | < 0.001 | 0.26 |
Psychiatric symptoms (0–33) | |||||
Baseline | 18.8 ± 4.8 | 18.8 ± 4.3 | 0.1 (-2.1 to 1.9) | 0.92 | |
4 weeks | 10.8 ± 5.0 | 13.3 ± 6.4 | -2.6 (-0.3 to -4.9) | < 0.001 | 0.16 |
8 weeks | 4.2 ± 3.5 | 11.4 ± 7.4 | -7.3 (-9.6 to -5.0) | < 0.001 | 0.31 |
Physical symptoms (0–21) | |||||
Baseline | 7.7 ± 3.5 | 6.6 ± 2.7 | 1.1 (-0.3 to 2,5) | 0.10 | |
4 weeks | 3.1 ± 2.3 | 4.7 ± 2.8 | -2.0 (-3.1 to -1.0) | < 0.001 | 0.06 |
8 weeks | 1.4 ± 1.5 | 3.7 ± 2.4 | -2.5 (-3.3 to -1.7) | < 0.001 | 0.33 |
Loss of interest in sex (0–3) | |||||
Baseline | 2.6 ± 0.8 | 2.4 ± 1.4 | 0.2 (-0.7 to 0.3) | 0.47 | |
4 weeks | 1.8 ± 1.0 | 1.9 ± 1.0 | -0.37 (-0.72 to -0.03) | 0.03 | 0.06 |
8 weeks | 1.6 ± 1.1 | 1.9 ± 1.0 | -0.52 (-0.89 to -0.15) | 0.006 | 0.09 |